Roche Among EU Fast-Track Hopefuls With Lymphoma Bispecific Mosunetuzumab
Executive Summary
Two companies are set to learn whether the European Medicines Agency will agree that their planned EU marketing applications merit an accelerated assessment.
You may also be interested in...
Roche Seeks Speedy EU Review For Second Bispecific Antibody
The European Medicines Agency was this week deciding whether to grant accelerated assessment for glofitamab.
Deal Watch: Amgen Taps Plexium's Expertise In Targeted Protein Degradation
Mersana will help J&J develop antibody-drug conjugates against three targets, while AstraZeneca out-licenses a candidate for peripheral artery disease to Regio.
EU Accelerated Assessment Tracker
The Pink Sheet's EU accelerated assessment tracker has been updated to include developments relating to investigational products from, among others, Janssen, Sanofi, Boehringer Ingelheim and Mirum.